We study basic, translational, and clinical aspects of gastrointestinal biology and tumorigenesis. Our research projects focus on the intestinal receptor guanylyl cyclase C (GUCY2C or GCC) and its hormone ligands guanylin and uroguanylin. We have identified this hormone-receptor signaling axis as a critical pathway in intestinal homeostasis, tumor suppression and enteroendocrine signaling. We have translated those discoveries into Phase I chemoprevention studies determining the potential ability of GUCY2C hormones to prevent colorectal cancer. Moreover, we are developing novel cancer immunotherapeutics targeting GUCY2C, including vaccines and CAR-T cells. These immunotherapies could be used to treat metastatic colorectal cancer, as well as esophageal, gastric, and pancreatic cancers, which often overexpress GUCY2C.
1020 Locust Street
Philadelphia, PA 19107